HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study.

Abstract
In a clinical phase-II study fludarabine phosphate was given to 20 patients with advanced chronic lymphocytic leukemia who had failed on prior conventional therapy. Fludarabine was administered at a dose of 25 mg/m2/d for 5 days. Treatment cycles were repeated every 4 weeks until maximal response, followed by two cycles for consolidation. Four of the 20 patients achieved complete remission and seven patients partial remission, resulting in an overall response rate of 55% (11/20). Fludarabine therapy was well tolerated, with mild myelosuppression and secondary infections comprising the predominant side effects. These data warrant further confirmation and a randomized comparison of fludarabine with established regimens, which is currently underway.
AuthorsW Hiddemann, R Rottmann, B Wörmann, A Thiel, M Essink, C Ottensmeier, M Freund, T Büchner, J van de Loo
JournalAnnals of hematology (Ann Hematol) Vol. 63 Issue 1 Pg. 1-4 (Jul 1991) ISSN: 0939-5555 [Print] Germany
PMID1715191 (Publication Type: Journal Article)
Chemical References
  • Antimetabolites, Antineoplastic
  • Vidarabine Phosphate
  • fludarabine phosphate
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic (therapeutic use)
  • Drug Evaluation
  • Female
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)
  • Male
  • Middle Aged
  • Remission Induction
  • Vidarabine Phosphate (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: